{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:13:38Z","timestamp":1790993618096,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jaci.2017.07.011","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T14:32:14Z","timestamp":1501597934000},"page":"654-662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Vitiligo: Mechanistic insights lead to novel treatments"],"prefix":"10.1016","volume":"140","author":[{"given":"Michael L.","family":"Frisoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.07.011_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/JID.2015.398","article-title":"The Vitiligo Impact Patient Scale (VIPs): development and validation of a vitiligo burden assessment tool","volume":"136","author":"Salzes","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaad.2009.03.022","article-title":"The burden of vitiligo: patient characteristics associated with quality of life","volume":"61","author":"Linthorst Homan","year":"2009","journal-title":"J Am Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","article-title":"Genetics of vitiligo","volume":"35","author":"Spritz","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2017.07.011_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.det.2016.11.004","article-title":"Presentations, signs of activity, and differential diagnosis of vitiligo","volume":"35","author":"Goh","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2017.07.011_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2014.12.003","article-title":"Why treatments do(n't) work in vitiligo: an autoinflammatory perspective","volume":"14","author":"Speeckaert","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2017.07.011_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.det.2016.11.008","article-title":"Phototherapy and combination therapies for vitiligo","volume":"35","author":"Esmat","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2017.07.011_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.det.2016.11.007","article-title":"Medical and maintenance treatments for vitiligo","volume":"35","author":"Passeron","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2017.07.011_bib8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/1523-1747.ep12469795","article-title":"In\u00a0vitro growth characteristics of melanocytes obtained from adult normal and vitiligo subjects","volume":"88","author":"Puri","year":"1987","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF00456389","article-title":"Growth defects of melanocytes in culture from vitiligo subjects are spontaneously corrected in\u00a0vivo in repigmenting subjects and can be partially corrected by the addition of fibroblast-derived growth factors in\u00a0vitro","volume":"281","author":"Puri","year":"1989","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2017.07.011_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2133.2001.03952.x","article-title":"Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo","volume":"144","author":"Jimbow","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib12","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.07.011_bib13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I interferon signature in the initiation of the immune response in vitiligo","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2017.07.011_bib14","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","article-title":"Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity","volume":"76","author":"Strassner","year":"2017","journal-title":"J Am Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib16","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jid.2016.10.048","article-title":"CXCR3 depleting antibodies prevent and reverse vitiligo in mice","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib20","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib21","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo\u2013controlled study","volume":"135","author":"Cavali\u00e9","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nri.2015.3","article-title":"Tissue-resident memory T cells: local specialists in immune defence","volume":"16","author":"Mueller","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.07.011_bib25","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.immuni.2014.12.007","article-title":"Tissue-resident memory T cells","volume":"41","author":"Schenkel","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2017.07.011_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1126\/science.1254536","article-title":"Resident memory CD8 T cells trigger protective innate and adaptive immune responses","volume":"346","author":"Schenkel","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.07.011_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1126\/science.1254803","article-title":"Skin-resident memory CD8+ T cells trigger a state of tissue-wide pathogen alert","volume":"346","author":"Ariotti","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.07.011_bib28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nature12110","article-title":"Immune surveillance by CD8\u03b1\u03b1+ skin-resident T cells in human herpes virus infection","volume":"497","author":"Zhu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2017.07.011_bib29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.07.011_bib30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2017.07.011_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aam6346","article-title":"Resident memory T cells in the skin mediate durable immunity to melanoma","volume":"2","author":"Malik","year":"2017","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2017.07.011_bib32","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo","volume":"362","author":"Jin","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.07.011_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/jid.2010.337","article-title":"Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP","volume":"131","author":"Birlea","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10875-008-9176-5","article-title":"Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED","volume":"28","author":"Moraes-Vasconcelos","year":"2008","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2017.07.011_bib35","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1126\/science.aaa1292","article-title":"Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals","volume":"346","author":"Maeda","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.07.011_bib36","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjd.13511","article-title":"Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation","volume":"172","author":"Tembhre","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/pcmr.12105","article-title":"Decreased regulatory T-cells and CD4+\/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo","volume":"26","author":"Dwivedi","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2017.07.011_bib38","doi-asserted-by":"crossref","first-page":"e37513","DOI":"10.1371\/journal.pone.0037513","article-title":"Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo","volume":"7","author":"Lili","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2017.07.011_bib39","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1755-148X.2012.01019.x","article-title":"Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells","volume":"25","author":"Zhou","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2017.07.011_bib40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional Treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2017.07.011_bib41","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1172\/JCI83465","article-title":"Targeting human melanoma neoantigens by T cell receptor gene therapy","volume":"126","author":"Leisegang","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.07.011_bib42","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.coi.2013.10.010","article-title":"Innate immune mechanisms in vitiligo: danger from within","volume":"25","author":"Richmond","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2017.07.011_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.12369","article-title":"Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo","volume":"269","author":"Harris","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2017.07.011_bib44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2016.09.008","article-title":"Understanding mechanisms of autoimmunity through translational research in vitiligo","volume":"43","author":"Strassner","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2017.07.011_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/1523-1747.ep12480976","article-title":"Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients","volume":"97","author":"Boissy","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib46","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1096\/fj.12-226779","article-title":"Basic evidence for epidermal H2O2\/ONOO\u2014mediated oxidation\/nitration in segmental vitiligo is supported by repigmentation of skin and eyelashes after reduction of epidermal H2O2 with topical NB-UVB-activated pseudocatalase PC-KUS","volume":"27","author":"Schallreuter","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.jaci.2017.07.011_bib47","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/jid.2012.37","article-title":"Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation","volume":"132","author":"Jin","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1034\/j.1600-0749.2001.140303.x","article-title":"Redox regulation in human melanocytes and melanoma","volume":"14","author":"Meyskens","year":"2001","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jaci.2017.07.011_bib49","doi-asserted-by":"crossref","first-page":"e1000523","DOI":"10.1371\/journal.pgen.1000523","article-title":"Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo","volume":"5","author":"Ren","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jaci.2017.07.011_bib50","first-page":"743","article-title":"From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo","volume":"47","author":"Yan","year":"2008","journal-title":"Int J Dematol"},{"key":"10.1016\/j.jaci.2017.07.011_bib51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2230.2002.01142.x","article-title":"Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study","volume":"27","author":"Patel","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib52","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2133.2009.09292.x","article-title":"Pseudocatalase and narrowband ultraviolet B for vitiligo: clearing the picture","volume":"161","author":"Gawkrodger","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib53","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1365-2133.2009.09252.x","article-title":"A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo","volume":"161","author":"Bakis-Petsoglou","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40257-015-0153-5","article-title":"Alternative Systemic Treatments for Vitiligo: A\u00a0Review","volume":"16","author":"Cohen","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib55","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","article-title":"Vitiligo pathogenesis and emerging treatments","volume":"35","author":"Rashighi","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2017.07.011_bib56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2230.2007.02514.x","article-title":"Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial","volume":"32","author":"Dell'Anna","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib57","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1468-3083.2006.02132.x","article-title":"Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study","volume":"21","author":"Middelkamp-Hup","year":"2007","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"10.1016\/j.jaci.2017.07.011_bib58","article-title":"Ginkgolide A\u00a0ameliorates LPS-induced inflammatory responses in\u00a0vitro and in\u00a0vivo","volume":"18","author":"Li","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2017.07.011_bib59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1472-6882-11-21","article-title":"Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial","volume":"11","author":"Szczurko","year":"2011","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.jaci.2017.07.011_bib60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2230.2003.01207.x","article-title":"Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo","volume":"28","author":"Parsad","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib61","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","article-title":"Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families","volume":"16","author":"Alkhateeb","year":"2003","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jaci.2017.07.011_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.det.2016.11.006","article-title":"Chemical-induced vitiligo","volume":"35","author":"Harris","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2017.07.011_bib63","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/jid.2011.16","article-title":"Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy","volume":"131","author":"van den Boorn","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib64","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/pcmr.12402","article-title":"Use of permanent hair\u00a0dyes and risk of vitiligo in women","volume":"28","author":"Wu","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2017.07.011_bib65","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/pcmr.12269","article-title":"Rhododendrol, a depigmentation-inducing phenolic compound, exerts melanocyte cytotoxicity via a tyrosinase-dependent mechanism","volume":"27","author":"Sasaki","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2017.07.011_bib66","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.0022-202X.2005.23653.x","article-title":"4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic\u00a0cell-mediated killing: relevance to vitiligo","volume":"124","author":"Kroll","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib67","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/jid.2013.268","article-title":"Oxidative stress\u2013induced calreticulin expression and translocation: new insights into the destruction of melanocytes","volume":"134","author":"Zhang","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib68","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.anndiagpath.2012.11.005","article-title":"Immunohistochemical expression of heat shock protein 70 in vitiligo","volume":"17","author":"Abdou","year":"2013","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.jaci.2017.07.011_bib69","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2008.45","article-title":"HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo","volume":"128","author":"Denman","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3005127","article-title":"Mutant HSP70 reverses autoimmune depigmentation in vitiligo","volume":"5","author":"Mosenson","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.07.011_bib71","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.immuni.2016.05.008","article-title":"Inflammasome-dependent induction of adaptive NK cell memory","volume":"44","author":"van den Boorn","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2017.07.011_bib72","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa061592","article-title":"NALP1 in vitiligo-associated multiple autoimmune disease","volume":"356","author":"Jin","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.07.011_bib73","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1073\/pnas.1222808110","article-title":"NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1\u03b2 processing via the NLRP1 inflammasome","volume":"110","author":"Levandowski","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2017.07.011_bib74","doi-asserted-by":"crossref","first-page":"e18907","DOI":"10.1371\/journal.pone.0018907","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2017.07.011_bib75","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjd.12691","article-title":"Inflammasome activation and vitiligo\/nonsegmental vitiligo progression","volume":"170","author":"Marie","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib76","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","article-title":"The role of IL-17 in vitiligo: a review","volume":"15","author":"Singh","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2017.07.011_bib77","series-title":"Lever's histopathology of the skin","first-page":"174","author":"Elder","year":"2009"},{"key":"10.1016\/j.jaci.2017.07.011_bib78","first-page":"534","article-title":"Treatment of generalized vitiligo with anti-TNF-\u03b1 agents","volume":"11","author":"AlGhamdi","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib79","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2017.07.011_bib80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjd.14016","article-title":"Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/jdv.13759","article-title":"New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases","volume":"31","author":"M\u00e9ry-Bossard","year":"2016","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"10.1016\/j.jaci.2017.07.011_bib82","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/archderm.140.10.1211","article-title":"Long-term follow-up study of segmental and focal vitiligo treated by autologous, noncultured melanocyte-keratinocyte cell transplantation","volume":"140","author":"Mulekar","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib83","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaad.2017.01.056","article-title":"Long-term follow-up of patients undergoing autologous noncultured melanocyte-keratinocyte transplantation for vitiligo and other leukodermas","volume":"77","author":"Silpa-Archa","year":"2017","journal-title":"J Am Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib84","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.det.2016.11.009","article-title":"Surgical therapies for vitiligo","volume":"35","author":"Mohammad","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2017.07.011_bib85","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","article-title":"Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib86","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib87","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/archderm.134.12.1532","article-title":"Nonsurgical repigmentation therapies in vitiligo","volume":"134","author":"Njoo","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib88","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.13432","article-title":"Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo","volume":"172","author":"Komen","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib89","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","article-title":"Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative","volume":"136","author":"van Geel","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib90","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamadermatol.2016.2501","article-title":"Sampling serum in patients with vitiligo to measure disease activity in the skin","volume":"152","author":"Rashighi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib91","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/jamadermatol.2016.2366","article-title":"Clinical significance of serum soluble CD molecules to assess disease activity in vitiligo","volume":"152","author":"Speeckaert","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib92","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jid.2017.01.033","article-title":"S100B is a potential disease activity marker in nonsegmental vitiligo","volume":"137","author":"Speeckaert","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2017.07.011_bib93","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.jid.2017.02.012","article-title":"Alterations of CXCL12 in serum of patients with vitiligo","volume":"137","author":"Speeckaert","year":"2017","journal-title":"J Invest Dermatol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917312630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917312630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:05:41Z","timestamp":1758791141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917312630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0091674917312630"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.07.011","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo: Mechanistic insights lead to novel treatments","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}